Buying Your GLP-1 Direct From the Maker: A Fair Review

A neutral look at LillyDirect and NovoCare self-pay programs: what they do well, and what a pharmacy channel leaves to you.

If you have watched the price of brand-name GLP-1 medicine over the last year, you have probably noticed something new: you can now buy it straight from the company that makes it. Eli Lilly sells Zepbound through a platform called LillyDirect. Novo Nordisk sells Wegovy through NovoCare Pharmacy. For a lot of people paying out of pocket, that sounds like the whole problem solved, and honestly, it solves a real part of it. These are legitimate programs dispensing genuine, FDA-approved brand medicine at transparent published prices. They are also not the same thing as having a clinic. Here is a fair look at what the direct channel does well, and what it quietly leaves up to you.

What "direct from the maker" actually means

Both of these are the manufacturers' own online self-pay pharmacies. You are not buying from a middleman or a marketplace. LillyDirect's self-pay pharmacy dispenses brand-name Zepbound (tirzepatide). NovoCare Pharmacy dispenses brand-name Wegovy (semaglutide). Both ship to your door, and both send refill reminders. The important thing to understand is that a prescription is still required either way. These platforms are pharmacies plus, in some cases, a connection to independent telehealth providers who can evaluate you and write that prescription. Using the platform does not guarantee any particular medicine will be prescribed for you; that decision belongs to a licensed provider, not to the company. In other words, the maker handles the product and the delivery, and a clinician, somewhere, still has to sign off.

One point in the plain-facts column: this is authentic, FDA-approved brand product. That is a real advantage over compounded semaglutide or tirzepatide, which are not FDA-approved and not brand-identical, and whose quality and results vary by individual. If you have been weighing the two, our post on compounded versus brand-name GLP-1 lays out the difference in more detail. (For the record: Zepbound and Mounjaro are Eli Lilly products, Wegovy and Ozempic are Novo Nordisk products, and New Hope Weight Loss and Wellness is not affiliated with either company.)

LillyDirect and the Zepbound vial

Lilly's lower prices come from a specific product choice: the single-dose vial. Instead of a pre-filled pen, the vial is a small glass container you draw from with a syringe. That extra step at home is exactly what lets Lilly price the vial below the pen. Through the LillyDirect Self Pay Journey Program, the approximate cash pricing runs about $299 a month for the 2.5 mg starting dose, about $399 for 5 mg, and about $449 for all of the higher approved doses (7.5, 10, 12.5, and 15 mg). Each of those is a 28-day supply. We are not going to walk you through drawing or injecting a dose here; that is something your prescriber should set up and show you, not a blog. If you want the full cost picture and how it compares, see our tirzepatide cost breakdown rather than a table we would just be repeating.

Two conditions matter. The self-pay price is cash only: you agree not to seek reimbursement from insurance or any third-party payer, and you cannot combine it with an insurance benefit. And these numbers are current as of 2026 and subject to change.

NovoCare and the Wegovy pen

NovoCare takes the pen route. As of 2026, new patients pay about $199 a month for the first two fills of the starter Wegovy doses through December 31, 2026, then about $349 a month after that. The higher-dose Wegovy HD 7.2 mg pen runs about $399 a month. Note the shape of that offer: the $199 is an introductory price with an expiration date, not a permanent rate, so it is worth reading the current terms before you count on it long term. Our semaglutide cost post keeps the running comparison.

There is a separate wrinkle people mix up. NovoCare also runs a $25-a-month savings-card offer, but that one requires commercial insurance and specifically excludes government insurance such as Medicare or Medicaid. That is a different path from the cash self-pay price described above, and the two do not stack. As for newer options, Wegovy HD (semaglutide 7.2 mg) was FDA-approved on March 19, 2026, and an oral form of semaglutide for weight management launched in the US in early 2026. Availability and pricing for those through the self-pay channel keep evolving, so check the manufacturer's current published terms rather than assuming.

The fine print worth reading twice

The one detail that trips people up is a refill window on the Zepbound vials. The reduced pricing on the higher-dose vials (7.5 through 15 mg) applies on your first fill and on refills placed within 45 days of your previous delivery. Let that window lapse, and the price for those higher doses climbs substantially. How much higher depends on the dose and the source, and the reported figures do not agree, so the honest answer is simply "substantially more, and it varies." The practical takeaway is that the low price rewards staying on schedule, which is easier when someone is actually helping you stay on track.

What the direct channel does not include

Here is the part the price sticker does not show. A manufacturer self-pay pharmacy is a dispensing pharmacy, not a clinic. It fills your prescription, ships it, and reminds you to reorder. What it does not do, on its own, is the ongoing clinical work: an individualized assessment of your health and history, structured guidance as your dose changes over time, proactive management of the nausea and other gastrointestinal side effects that are common early on, lab and metabolic monitoring, and attention to other conditions you may be managing at the same time. The platforms can connect you to independent telehealth providers, but that involvement is often episodic, a check-in to authorize the prescription rather than a continuous relationship. None of that is a knock on the pharmacies. It is just a description of what a pharmacy is and is not designed to do.

Using the maker and a clinic together

The useful way to think about this is not "manufacturer versus clinic." For many people the two fit together. You can source authentic, affordable, FDA-approved brand medicine through the manufacturer's self-pay program, and still have a dedicated clinic providing the oversight that a dispensing channel does not: the assessment, the titration guidance, the side-effect coaching, the lab work, and the steady point of contact when something feels off. That continuity is most of what determines whether the medicine actually works out for you over months, not weeks. Our post on how follow-up care works walks through what that ongoing support looks like in practice. Dr. Anjmun Sharma, MD, built New Hope's program around exactly that kind of continuity, and it is worth remembering that no GLP-1 is a treatment for any non-obesity condition, and that starting, stopping, or changing any prescription is a decision for your prescriber, never something to do on your own.

So is buying direct from the maker a good idea? For getting real brand medicine at a transparent price, it can be a genuinely good one, and it beats gambling on unregulated alternatives. Just go in clear-eyed: you are buying a product and a delivery service, the low price rewards staying on schedule, the promotional rates have expiration dates, and the care part is still yours to arrange. Pair the affordable source with a real clinical relationship, and you get the best of both.

Frequently asked questions

This article is informational only and not medical advice. Speak with a licensed physician before starting or changing any GLP-1 therapy. Individual results vary. New Hope Weight Loss is a physician-supervised medical weight loss clinic in Costa Mesa, CA. Eligibility for treatment is determined during the medical consultation. Compounded semaglutide and compounded tirzepatide are not the same products as Wegovy®, Ozempic®, Mounjaro®, or Zepbound®.